3-4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine
• 英文别名: 2-(Hydroxymethyl)-1-methylpyrrolidine-3,4-diol
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: UBVOJPDDTVFNFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] RORγ MODULATORS<br/>[FR] MODULATEURS DE ROR&Ggr;
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015035278A1

  公开（公告）日：2015-03-12

  Described are RORγ modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其药学上可接受的盐，其中所有取代基在此处定义。该发明包括公式I化合物的立体异构体形式，包括立体异构纯、立体混合和消旋形式，以及其互变异构体。还提供了包含相同化合物的药物组合物。这些化合物和组合物在调节细胞中的RORγ活性的方法以及治疗患有疾病或紊乱的受试者的方法中是有用的，其中受试者在调节RORγ活性方面会从中获益，例如自身免疫和/或炎症性疾病。
• Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
  申请人：——

  公开号：US20040082641A1

  公开（公告）日：2004-04-29

  The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

  本发明提供了治疗和预防早期心脏和早期心血管疾病的方法，例如缺血性疾病，如左心室肥大，冠状动脉疾病，高血压，急性高血压紧急情况，心肌病，心力衰竭，运动耐受性，慢性心力衰竭，心律失常，心脏心律失常，晕厥，动脉硬化，轻度慢性心力衰竭，心绞痛，心脏旁路再闭塞，间歇性跛行（闭塞性动脉硬化），舒张功能和收缩功能障碍，以及通过给予糖原磷酸化酶抑制剂化合物来提高心脏移植的成功率。
• TRICYCLIC GYRASE INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160222015A1

  公开（公告）日：2016-08-04

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本发明涉及具有公式I结构的化合物及其药学适宜的盐、酯和前药，这些化合物可用作具有抗菌作用的三环酶抑制剂。还考虑了相关的制药组合物、用途和制备这些化合物的方法。
• Use of 3,4-dihydroxy-2-hydroxymethylpyrrolidine for the treatment of diabetes
  申请人：NOVO NORDISK A/S

  公开号：EP0884050A1

  公开（公告）日：1998-12-16

  (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines can be used for the treatment of diabetes.

  (2R,3R,4R)-3,4-二羟基-2-羟甲基吡咯烷和其他取代的 2-甲基吡咯烷可用于治疗糖尿病。
• Use of 2-alkylpyrrolidines for the treatment of diabetes
  申请人：NOVO NORDISK A/S

  公开号：EP1040827A2

  公开（公告）日：2000-10-04

  (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines can be used for the treatment of diabetes.

  (2R,3R,4R)-3,4-二羟基-2-羟甲基吡咯烷和其他取代的 2-甲基吡咯烷可用于治疗糖尿病。